Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioSurface Technology

This article was originally published in The Gray Sheet

Executive Summary

Temporarily halts clinical trials of its Acticel wound dressing for treatment of burn patient donor site wounds after finding an "equivocal" reduction in average healing time for the indication. Pilot studies had shown a "clinically significant" time reduction, according to the company. BioSurface is conducting an "intensive" analysis of both data and study design to determine how best to proceed. Acticel trials in five other indications, such as deep partial thickness burns and pressure ulcers ("The Gray Sheet" Jan. 11, p. 16), will continue.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT000317

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel